There has been a lot current discussion and debate surrounding cannabis in Canada, which includes the prescribing of health-related cannabis for therapeutic purposes. Specific commentators – which includes the Canadian Healthcare Association (CMA) – have denounced the prescribing of cannabis for health-related purposes due to a perceived lack of proof associated to the drug’s efficacy, harms, and mechanism of action. In this commentary, we present arguments in favour of prescribing health-related cannabis in Canada. We think the anti-cannabis position taken by CMA and other commentators is not completely proof-primarily based. Applying the instance of neuropathic discomfort, we present and summarize the clinical proof surrounding smoked or vapourized cannabis, which includes current proof pertaining to the effectiveness of cannabis in comparison to current common pharmacotherapies for neuropathy. Additional, we outline how the issues expressed regarding cannabis‘ mechanism of action are inconsistent with existing choice-producing processes associated to the prescribing of lots of typical pharmaceuticals. Ultimately, we go over possible secondary public well being positive aspects of prescribing cannabis for discomfort-associated problems in Canada and North America.
Copyright © 2018 Elsevier B.V. All rights reserved.
PMID: 26451996 DOI: 10.17269/cjph.106.4926
Lake S, Kerr T, Montaner J1.